经动脉化疗栓塞联合全身治疗肝细胞癌：最新进展
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update.
作者信息
Rizzo Alessandro, Ricci Angela Dalia, Brandi Giovanni
机构信息
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.
Medical Oncology Unit, National Institute of Gastroenterology, "Saverio de Bellis" Research Hospital, 70013 Castellana Grotte, Italy.
出版信息
J Pers Med. 2022 Oct 29;12(11):1788. doi: 10.3390/jpm12111788.
Abstract
Recent years have seen the advent of novel treatment options for hepatocellular carcinoma (HCC). Given a strong biological rationale supporting this strategy, multiple studies have explored the role of combination treatments including locoregional plus systemic therapies to produce a synergistic effect and enhance antitumor activity. Among locoregional therapies, several clinical trials assessing trans-arterial chemoembolization (TACE) have been recently presented and published. In the current paper, we discuss available evidence and current and future research on combined TACE and systemic treatments, including antiangiogenic agents, immune checkpoint inhibitors, and immune-based combinations for HCC patients.
摘要
近年来，肝细胞癌（HCC）出现了新的治疗选择。鉴于有强有力的生物学理论支持这一策略，多项研究探讨了联合治疗的作用，包括局部区域治疗与全身治疗相结合，以产生协同效应并增强抗肿瘤活性。在局部区域治疗中，最近已经公布并发表了几项评估经动脉化疗栓塞术（TACE）的临床试验。在本文中，我们讨论了关于TACE与全身治疗联合应用的现有证据以及当前和未来的研究，这些全身治疗包括抗血管生成药物、免疫检查点抑制剂以及针对HCC患者的基于免疫的联合治疗。
相似文献
1
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update.
J Pers Med. 2022 Oct 29;12(11):1788. doi: 10.3390/jpm12111788.
2
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.
3
Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
Expert Opin Investig Drugs. 2022 Apr;31(4):379-391. doi: 10.1080/13543784.2022.2008355. Epub 2021 Nov 25.
4
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.
Chin J Cancer Res. 2024 Apr 30;36(2):167-194. doi: 10.21147/j.issn.1000-9604.2024.02.06.
5
Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
BMC Cancer. 2020 Feb 19;20(1):135. doi: 10.1186/s12885-020-6613-1.
6
The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
Int J Mol Sci. 2023 May 11;24(10):8598. doi: 10.3390/ijms24108598.
7
Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts.
Cancers (Basel). 2024 Jun 28;16(13):2387. doi: 10.3390/cancers16132387.
8
Role of locoregional therapies in the wake of systemic therapy.
J Hepatol. 2020 Feb;72(2):277-287. doi: 10.1016/j.jhep.2019.09.023.
9
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
10
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293-313. doi: 10.1038/s41575-020-00395-0. Epub 2021 Jan 28.
引用本文的文献
1
Exploration of the Mechanism of Action of in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation.
J Hepatocell Carcinoma. 2025 Aug 28;12:1973-1990. doi: 10.2147/JHC.S527095. eCollection 2025.
2
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma: survival outcomes and prognostic factors from a systematic review and meta-analysis.
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):587-607. doi: 10.21037/hbsn-2025-115. Epub 2025 Jul 25.
3
Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.
Hum Vaccin Immunother. 2025 Dec;21(1):2540143. doi: 10.1080/21645515.2025.2540143. Epub 2025 Aug 17.
4
Outcome prediction model for patients with unresectable hepatocellular carcinoma treated with targeted therapy.
Sci Rep. 2025 Aug 12;15(1):29608. doi: 10.1038/s41598-025-13799-2.
5
Donafenib lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study.
Quant Imaging Med Surg. 2025 Aug 1;15(8):7235-7245. doi: 10.21037/qims-2025-364. Epub 2025 Jul 15.
6
Dual-phase multiobjective Bayesian optimization method for estimating hepatocellular carcinoma dynamics parameters from PET/CT scans.
Quant Imaging Med Surg. 2025 Aug 1;15(8):6654-6666. doi: 10.21037/qims-2024-2767. Epub 2025 Jul 29.
7
Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma.
Innovation (Camb). 2025 Apr 11;6(7):100910. doi: 10.1016/j.xinn.2025.100910. eCollection 2025 Jul 7.
8
Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Immunotargets Ther. 2025 Jul 17;14:761-771. doi: 10.2147/ITT.S495451. eCollection 2025.
9
Prognostic value of platelet-to-lymphocyte ratio in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
BMC Gastroenterol. 2025 Jun 6;25(1):437. doi: 10.1186/s12876-025-04028-1.
10
Causal association of cholesterol metabolism-related proteins with hepatocellular carcinoma and dysfunction-associated steatotic liver disease: a mendelian randomization study.
Discov Oncol. 2025 Jun 2;16(1):987. doi: 10.1007/s12672-025-02321-9.
本文引用的文献
1
Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
Cureus. 2022 Aug 26;14(8):e28439. doi: 10.7759/cureus.28439. eCollection 2022 Aug.
2
Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis.
Front Oncol. 2022 Sep 13;12:914385. doi: 10.3389/fonc.2022.914385. eCollection 2022.
3
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.
Liver Cancer. 2022 Jun 15;11(5):440-450. doi: 10.1159/000525500. eCollection 2022 Sep.
4
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Clin Exp Med. 2023 Jul;23(3):579-590. doi: 10.1007/s10238-022-00873-6. Epub 2022 Aug 26.
5
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Curr Oncol. 2022 Aug 4;29(8):5489-5507. doi: 10.3390/curroncol29080434.
6
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul.
7
New concepts in the treatment of hepatocellular carcinoma.
United European Gastroenterol J. 2022 Sep;10(7):765-774. doi: 10.1002/ueg2.12286. Epub 2022 Aug 16.
8
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
9
Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Front Oncol. 2022 Jun 16;12:898964. doi: 10.3389/fonc.2022.898964. eCollection 2022.
10
Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
J Cancer Res Clin Oncol. 2023 Mar;149(3):969-978. doi: 10.1007/s00432-022-04057-3. Epub 2022 Jun 30.
Zotero 插件